Abstract:Abstract Currently available biotherapeutics for the treatment of osteoporosis lack explicit mechanisms for bone localization, potentially limiting efficacy and inducing unintended off-target toxicities. While various strategies have been explored for targeting the bone surface, critical aspects remain poorly understood, including the optimal affinity ligand, the role of binding avidity and circulation time, and, perhaps most importantly, whether or not this strategy can enhance the functional activity of clinically relevant protein therapeutics. To investigate, we generated fluorescent proteins (e.g., mCherry) with site-specifically attached small molecule (bisphosphonate, BP) or peptide (deca-aspartate, D10) affinity ligands. While both affinity ligands successfully anchored fluorescent protein to the bone surface, quantitative radiotracing revealed only modest femoral and vertebral accumulation and suggested a need for enhanced circulation time. To achieve this, we fused mCherry to the Fc fragment of human IgG1 and attached D10 peptides to each C-terminus. mCherry-Fc-D10 demonstrated ~80-fold increase in plasma exposure and marked increases in femoral and vertebral accumulation (13.6 ± 1.4% and 11.4 ± 1.3% of the injected dose/gram [%ID/g] at 24 hours, respectively). To determine if bone surface targeting could enhance the efficacy of a clinically relevant therapeutic, we generated a bone-targeted sclerostin neutralizing antibody, anti-sclerostin-D10. The targeted antibody demonstrated marked increases in bone accumulation and retention (20.9 ± 2.5% and 19.5 ± 2.5% ID/g in femur and vertebrae at 7 days) and enhanced effects in a murine model of ovariectomy-induced bone loss (BV/TV, connectivity density, and structure model index all increased [p < 0.001] vs. untargeted anti-sclerostin). Collectively, our results indicate the importance of both bone affinity and circulation time in achieving robust targeting of therapeutic proteins to the bone surface and suggest that this approach may enable lower doses and/or longer dosing intervals without reduction in biotherapeutic efficacy. Future studies will be needed to determine the translational potential of this strategy and its potential impact on off-site toxicities.

Synthesis, characterization and biodistribution studies of (125)I-radioiodinated di-PEGylated bone targeting salmon calcitonin analogue in healthy rats

Pentapeptide-decorated Silica Nanoparticles Loading Salmon Calcitonin for in Vivo Osteoporosis Treatment with Sustained Hypocalcemic Effect

Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis

Injectable Carrier for Zero-Order Release of Salmon Calcitonin.

Sulfated alginate based complex for sustained calcitonin delivery and enhanced osteogenesis

In vivo assessment of bone repair by an injectable nanocomposite scaffold for local co-delivery of autologous platelet-rich plasma and calcitonin in a rat model

Calcium Bisphosphonate Nanoparticles with Chelator-Free Radiolabeling to Deplete Tumor-Associated Macrophages for Enhanced Cancer Radioisotope Therapy

Calcitonin-Loaded Thermosensitive Hydrogel for Long-Term Antiosteopenia Therapy.

Preparation and in vitro-in vivo evaluation of salmon calcitonin-loaded polymeric nanoparticles

Salmon Calcitonin-Loaded Plga Microspheres/Calcium Phosphate Cement Composites For Osteoblast Proliferation

Thermosensitive Polysaccharide Hydrogel As a Versatile Platform for Prolonged Salmon Calcitonin Release and Calcium Regulation

Controllable release of salmon-calcitonin in injectable calcium phosphate cement modified by chitosan oligosaccharide and collagen polypeptide

Transdermal Delivery of Salmon Calcitonin Using a Dissolving Microneedle Array: Characterization, Stability, and In vivo Pharmacodynamics

Supramolecular Nanoparticles of Calcitonin and Dipeptide for Long-Term Controlled Release

Preparation, characterization and biodistribution of 99mTc-HYNIC-ACPDP as a novel potential bone imaging agent

Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis

Enhancing Bone Regeneration and Osseointegration using rhPTH(1-34) and Dimeric R25CPTH(1-34) in an Osteoporotic Beagle Model

Bone-targeting Polymer Vesicles for Simultaneous Imaging and Effective Malignant Bone Tumor Treatment.

Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model

Affinity targeting of therapeutic proteins to the bone surface – local delivery of sclerostin neutralizing antibody enhances efficacy

Preparation and in Vitro Releasing of Salmon Calcitonin Carried Porous Injectable Calcium Phosphate Bone Cement